维奈克拉联合诱导化疗治疗新诊断急性髓系白血病:一项事后倾向评分匹配队列研究
该事后倾向评分匹配分析比较了维奈克拉联合强化化疗与单纯强化化疗在新诊断急性髓系白血病或高危骨髓增生异常综合征患者中的活性。匹配队列共279例,维奈克拉联合组85例,单纯化疗组194例。联合组MRD阴性复合完全缓解率更高(86% vs 61%,OR 3.2,P=0.0028),至异基因造血干细胞移植累积发生率更高(79% vs 57%,HR 1.52,P=0.012),无事件生存改善(HR 0.57,P=0.030),但总生存无显著差异(HR 0.63,P=0.13)。
要点
- 维奈克拉联合强化化疗组MRD阴性复合完全缓解率为86%,单纯化疗组为61%(OR 3.2,95%CI 1.5-6.7,P=0.0028)。
- 联合组至异基因HSCT累积发生率为79%,单纯化疗组为57%(HR 1.52,95%CI 1.11-2.08,P=0.012)。
- 联合组无事件生存改善(HR 0.57,95%CI 0.34-0.95,P=0.030),但总生存无显著差异(HR 0.63,95%CI 0.35-1.1,P=0.13)。
核心结论
- 维奈克拉联合强化诱导化疗可诱导深度MRD阴性缓解,使患者能在首次缓解期过渡至异基因HSCT,并改善无事件生存。
- 这些结果突显了在强化诱导化疗基础上加用维奈克拉在欧洲白血病网(European LeukemiaNet)各风险组中的增量获益,并为未来确证性前瞻性临床试验的入组提供了基准。
研究设计与样本
- 本研究为事后倾向评分匹配分析,数据来自前瞻性临床试验(NCT03214562、NCT02115295和NCT01289457)。
- 研究地点为美国德克萨斯州休斯顿的德克萨斯大学MD安德森癌症中心,时间为2010年3月29日至2021年6月15日。
- 纳入标准为年龄18岁及以上、新诊断急性髓系白血病或高危骨髓增生异常综合征,并接受含嘌呤类似物联合蒽环类和阿糖胞苷的方案(联合或不联合维奈克拉)治疗。
- 倾向评分匹配队列共279例患者(中位年龄49岁[IQR 39-57];男性131例[47%],女性148例[53%]),其中维奈克拉联合强化化疗组85例,单纯强化化疗组194例。
- 主要目标为MRD阴性复合完全缓解率和至异基因HSCT的累积发生率;所有在两个治疗周期(诱导和再诱导)内获得缓解的患者均纳入分析。
主要发现
- 中位随访30个月(95%CI 26-36)后,维奈克拉联合强化化疗组74例中64例(86%)获得MRD阴性复合完全缓解,单纯强化化疗组140例中86例(61%)获得(OR 3.2,95%CI 1.5-6.7;P=0.0028)。
- 缓解患者中,联合组至异基因HSCT的总体累积发生率为79%(95%CI 67-88),单纯化疗组为57%(95%CI 49-65)(HR 1.52,95%CI 1.11-2.08;P=0.012)。
- 联合组无事件生存改善,中位未达到(NR;95%CI NR-NR),单纯化疗组为14.3个月(95%CI 10.7-33.5)(HR 0.57,95%CI 0.34-0.95;P=0.030)。
- 两组总生存无显著差异,联合组中位NR(95%CI 24-NR),单纯化疗组为32个月(95%CI 19-NR)(HR 0.63,95%CI 0.35-1.1;P=0.13)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venetoclax combined with intensive chemotherapy has been shown to be safe with promising activity in fit patients with newly diagnosed acute myeloid leukaemia. The aim of this study was to compare the activity of venetoclax plus intensive chemotherapy with intensive chemotherapy alone. METHODS: This was a post-hoc propensity score matched analysis of prospective clinical trials (NCT03214562, NCT02115295, and NCT01289457) in patients at The University of Texas MD Anderson Cancer Center, Texas, USA between March 29, 2010, and June 15, 2021. Eligible patients were aged 18 years and older, and had newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome, and were treated within trials incorporating purine analogues with an anthracycline and cytarabine either with venetoclax plus intensive chemotherapy or with intensive chemotherapy alone. Patients in the venetoclax plus intensive chemotherapy cohort were matched with patients in the intensive chemotherapy cohort. Morphological response and measurable residual disease (MRD) was assessed using bone marrow aspiration and biopsy and eight-colour multiparameter flow cytometry. The primary objectives were rate of MRD negative composite complete response and cumulative incidence of transition to allogeneic haematopoietic stem-cell transplantation (HSCT). All patients who had response within two treatment cycles (induction and re-induction) were included in the analyses. Secondary objectives included assessment of event-free and overall survival. FINDINGS: The propensity matched cohort included 279 patients (median age 49 years [IQR 39-57]; 131 [47%] were men and 148 [53%] were women); 85 in the venetoclax plus intensive chemotherapy cohort and 194 in the intensive chemotherapy cohort. After a median follow up of 30 months (95% CI 26-36), 64 (86%) of 74 patients in the venetoclax plus intensive chemotherapy cohort had an MRD-negative composite complete response rate compared with 86 [61%] of 140 patients in the intensive chemotherapy cohort (odd ratio 3·2 [95% CI 1·5-6·7]; p=0·0028). The overall cumulative incidence of allogeneic HSCT in responding patients was higher with venetoclax plus intensive chemotherapy than intensive chemotherapy (79% [95% CI 67-88] vs 57% [49-65]; hazard ratio [HR] 1·52 [95% CI 1·11-2·08]; p=0·012). Venetoclax plus intensive chemotherapy improved event-free survival (median not reached [NR; 95% CI NR-NR] vs 14·3 months [10·7-33·5]; HR 0·57 [95% CI 0·34-0·95]; p=0·030), but overall survival did not significantly differ between the two cohorts (median NR [95% CI 24-NR] vs 32 months [19-NR]; HR 0·63 [95% CI 0·35-1·1], p=0·13). INTERPRETATIONS: Venetoclax combined with intensive induction chemotherapy induced deep MRD-negative remissions, allowing transition to allogeneic HSCT in first remission, and improvement in event-free survival. These results highlight the incremental benefit of venetoclax added to intensive induction chemotherapy across European LeukemiaNet risk groups, and serve as a benchmark to inform enrolment on future confirmatory prospective clinical trials. FUNDING: None.
引用
- Lachowiez CA, Reville PK, Kantarjian H, et al. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022. PMID: 35483396. doi:10.1016/S2352-3026(22)00076-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。